Effect of Sitagliptin in Impaired Glucose Tolerance

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to examine the safety and efficacy of sitagliptin 100 mg every day (q.d.) in improving hyperglycemia and endothelial dysfunction in subjects with impaired glucose tolerance.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Taiwan University Hospital
• Treatments: Sitagliptin Phosphate

Criteria

Inclusion Criteria:

1. Chinese subjects aged 40-65 years with fasting plasma glucose < 100 mg/dL and OGTT 2-hour glucose 140-199 mg/dL.

2. Subjects are judged to be in otherwise general good health based on medical history, physical examination, and routine laboratory tests.

3. Subject has an understanding of the study procedures, alternative treatments available and risk involved with the study, and voluntarily agrees to participate by giving written informed consent.

4. Non-sterilized premenopausal female agrees to receive pregnancy test to confirm the non-pregnancy status and use adequate contraceptive methods to prevent pregnancy during the study period. Patient status should be confirmed by pregnancy test before enrollment.

Exclusion Criteria:

1. Evidence of diabetes (FPG> 125 mg/dL, or OGTT 2-hour glucose>=200 mg/dL, or current use of an anti-diabetic agents, except for history of gestational diabetes).

2. History of intolerance or hypersensitivity or contraindication as mentioned in the approved package insert (appendix).

3. Patient has any of the following disorders within the past 6 months: acute coronary syndrome (e.g., MI or unstable angina), coronary artery intervention (e.g., CABG or PTCA), stroke or transient ischemic neurological disorder.

4. Patient has new or worsening signs or symptoms of coronary heart disease within the past 3 months.

5. Patient has a BMI > 40 kg/m2.

6. Patient is on or likely to require more than 14 consecutive days or repeated courses of pharmacologic doses of corticosteroids. Note: inhaled, nasal, and topical corticosteroids are permitted.

7. Patient is on or likely to require treatment with immunosuppressive agents (e.g., cyclosporine, methotrexate).

8. Advanced renal insufficiency (estimated creatinine clearance < 50 ml/min).

9. Severe hepatic insufficiency (Child-Pugh score > 9, see Appendix).